'Two Different Choices:' Mazda Explains How the New CX-5 and CX-50 Can Coexist
Speaking with
Motor1
, Mazda North America's VP of Strategic Planning, Stefan Meisterfeld, says that the
CX-5
and
CX-50
offer two unique choices for two different types of customers.
2026 Mazda CX-5
Photo by: Mazda
2025 Mazda CX-50 Hybrid
Photo by: Jeff Perez / Motor1
"We believe in the coexistence of these two [vehicles] because this is the largest segment in the industry," Meisterfeld notes. "We do see customers who lean more towards the urban, sophisticated direction—which is obviously CX-5. But we also see the more rugged and more adventure-oriented customer in the CX-50."
"We see them coexist perfectly next to each other," Meisterfeld continues. "In fact, I think we have a unique proposition here as one of the very few—if not the only—manufacturer that offers these two different choices in this segment."
It's hard to disagree. Mazda sold more than 134,000 examples of the CX-5 in 2024, and more than 80,000 CX-50s, putting them first and third on the automaker's sales chart, respectively. Only the subcompact CX-30 finished better than the CX-50.
Photo by: Mazda
This year also marks the first full year of sales for the new CX-50 Hybrid, which combines a Toyota hybrid system with the company's 2.5-liter four-cylinder engine. As we note in our review, the more efficient CX-50
should only help bolster sales
.
Mazda has already confirmed the arrival of a hybrid CX-5 in 2027, but it won't use the same Toyota unit as the CX-50.
"The CX-50, as you know, is built alongside Toyota vehicles in our plant here in the US," Meisterfeld tells us. "The [new CX-5] will be built in Japan, and we believe that the Mazda hybrid system will have unique characteristics that will just fit perfectly for this vehicle."
The 2026 Mazda CX-5 goes on sale toward the end of the year, but we'll have to wait for official pricing.
More On The CX-5
Mazda's Skyactiv-Z Will Be 'The Ideal Internal Combustion Engine'
The Next-Generation Mazda CX-5 Will Be Hybrid
Share this Story
X
Got a tip for us? Email:
tips@motor1.com
Join the conversation
(
)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
The White House just got another useless gold ornament.
Billionaire Apple CEO Tim Cook presented Donald Trump with a gaudy personalized gift boasting a 24-karat gold base as the tech giant woo'ed the president at the White House on Wednesday. Cook dropped in to the White House bearing his golden gift to announce the tech company's extra $100 billion investment in American manufacturing as the president still waves the threat of tariffs. The president started the press conference by calling Cook, 'One of the great and most esteemed business leaders and geniuses and innovators anywhere in the world.'
Yahoo
16 minutes ago
- Yahoo
Rate cuts could be weeks away. Here's how much history says stocks could rise as the Fed eases policy.
Investors expect the Fed to resume rate cuts next month. Historically, rate cuts have led to strong S&P 500 gains, but there have been exceptions. Here's what history says about how the market behaves once rate cuts start back up. After a weak few months of job growth, investors are banking on rate cuts from the Federal Reserve at their September meeting, and history shows cuts could be like rocket fuel for stocks in the months that follow. LPL Financial recently conducted an analysis of how stocks have performed from the first rate cut in a rate-reduction cycle until the eventual start of a new hiking cycle. On average, the S&P 500 has returned 30.3% during the nine periods when rates have been on the decline since 1974. The median return during those periods was 13.3%. Returns have been positive in six of those nine cycles. "Using history and prior Fed cutting cycles as a guide, some upside potential may remain for the second half of 2025," Jeff Buchbinder, LPL's chief equity strategist, said in the August 5 report. "But of course, past performance does not guarantee future results, and a new tariff regime not seen since the 1930s could slow earnings growth and fuel volatility." The largest market surges came in the lead up to the dot-com bubble, when the S&P 500 rose 161% from 1995 to 1999, the analysis showed. Other big gains included 62.8% from 1984 to 1993, and 38.2% from 2019 to 2021. But rate cuts aren't always a tailwind, especially during recessionary periods where the Fed acts too late. The market fell 23.5% during the 2007-2009 rate-cutting cycle, and from 2001-2004, the S&P 500 dropped 9.6%. This time around, Buchbinder said it's not a sure thing that rate cuts will be a boon for stocks, with ebullient investor sentiment having pushed up the market to new highs despite uncertainty remaining about the health of the economy. The market has also risen 12% already since the Fed's first cut of the cycle last September. "The delayed effects of trade policy are likely to weigh on the economy in the second half, leading to weaker labor market demand," Buchbinder wrote. "Recent market complacency toward trade policy and an economic narrative dependent upon strong economic data has caught our attention in recent weeks as a potential point of weakness." It's also not a guarantee the Fed continues to ease policy in the months ahead. Economists at Morgan Stanley and Bank of America both see the central bank keeping rates steady for the rest of 2025 despite CME FedWatch data showing investors pricing in 93.2% odds that the Fed cuts in next month. Given the apparent heightened levels of risk at the moment, Buchbinder said a conservative approach could be the best way forward in the near term. The firm likes growth stocks, large caps, and the financials and communication services sectors, he said. "Bottom line, investors may be well served by bracing for occasional bouts of volatility given how much optimism is currently reflected in equity prices," Buchbinder said. The firm's short-term asset allocation committee "advises against increasing portfolio risk beyond benchmark targets currently and continues to monitor tariff negotiations, economic data, earnings, the bond market, and various technical indicators to identify a potentially more attractive entry point to add equities on weakness," he added. Read the original article on Business Insider Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
16 minutes ago
- Yahoo
Becton, Dickinson and Company Submits Application to the FDA for a New, At-Home HPV Test
Becton, Dickinson and Company (NYSE:BDX) is one of the . On July 31, Becton, Dickinson and Company (NYSE:BDX) announced that it submitted an application to the U.S. FDA for a new, at-home HPV test. The new HPV test focuses on patients to self-collect a sample at their home using a swab, the size of a Q-tip, simplifying lab processing. According to BD, this method also reports more high-risk strains of HPV compared to other tests on the market today. A person wearing a state-of-the-art medical device for nerve conduction tests. 'We envision a world where women are empowered with access and a choice for their HPV screening, whether it be in a routine visit at the doctor's office or the comfort and privacy of their own home via a self-collected sample. Cervical cancer and the loss of more than 4,000 women per year to this devastating disease is preventable, and we believe at-home testing is an important leap forward to our goal of eliminating this type of cancer,' said Nikos Pavlidis, president of BD Diagnostic Solutions. BD's new HPV test will include a state-of-the-art self-collection swab technology that also offers convenient mailing from home to the lab, supporting broader participation in cervical cancer screening programs. The self-collected swab requires no manual sample preparation by clinical laboratory technologists. This process will allow them to focus on higher-value work. Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company that focuses on the development, manufacturing, and sale of various medical supplies, devices, diagnostic products, and laboratory equipment. While we acknowledge the potential of BDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
